Crinetics Pharmaceuticals (CRNX) Misses Q2 EPS by 8c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($0.94), $0.08 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $390 thousand versus the consensus estimate of $467.27 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Senior Iranian Official To Reuters: Tehran Is Reviewing U.S. Response To Its Proposal To End Hostilities
• Darden Restaurants (DRI) call put ratio 1.1 calls to 1 put into the expected release of quarter results
• Rubio: Iran Meeting Was Positive But Not A Breakthrough - Bloomberg